Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 8551–8600 of 75459
On June 18, 2024, Billy Barnard, the Interim Chief Financial Officer of flyExclusive, Inc. (the “Company”), resigned, effective immediately.
Todd Klein did not stand for re-election at the annual meeting of stockholders held on June 20, 2024 (the “Annual Meeting”).
On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).
On June 20, 2024, Michael Matlock notified Toast, Inc. (the “Company”) that he will resign as the Company’s Chief Accounting Officer and principal accounting officer, effective August 9, 2024.
On June 24, 2024, Walter Hunt notified Solitario Resources Corp. (“Solitario”) that he will retire as the Chief Operating Officer of Solitario effective June 30, 2024.
Joseph G. Flanagan, a member of the Board of Directors (the “Board”) of GoHealth, Inc. (the “Company”), informed the Company of his intent to resign from the Board effective June 25, 2024.
On June 17, 2024, Mr. Rene Mladosich resigned his employment as General Manager of the Company at San Jose de Gracía.
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
Alexander J. Bruni, the Company’s Executive Vice President & Chief Financial Officer, has, at the request of the Company, resigned from his position as an officer of the Company, effective June 21, 2024.
Charles Dadswell, Ankur Dhingra and William (Bill) Chase ceased to be directors of GRAIL, LLC, the Company’s predecessor.
Charles Dadswell, Ankur Dhingra and William (Bill) Chase ceased to be directors of GRAIL, LLC, the Company’s predecessor.
Charles Dadswell, Ankur Dhingra and William (Bill) Chase ceased to be directors of GRAIL, LLC, the Company’s predecessor.
Richard A. Farmar, III, Andrew C. Holzwarth and Robert S. Janney, directors of Blue Ridge Bankshares, Inc. (the “Company”) and Blue Ridge Bank, National Association (the “Bank”), a wholly-owned subsidiary of the Company, each notified the Company and the Bank that they are voluntarily retiring from the Boards of Directors of the Company and the Bank effective as of the date of the Company’s 2024 annual meeting of shareholders
the Company announced that Mensel D. Dean, Jr. and Larry Dees, directors of the Company and the Bank, are retiring from the Boards of Directors of the Company and the Bank effective as of the date of the Annual Meeting pursuant to the Company’s mandatory director retirement age provision set forth in the Company’s Bylaws
Richard A. Farmar, III, Andrew C. Holzwarth and Robert S. Janney, directors of Blue Ridge Bankshares, Inc. (the “Company”) and Blue Ridge Bank, National Association (the “Bank”), a wholly-owned subsidiary of the Company, each notified the Company and the Bank that they are voluntarily retiring from the Boards of Directors of the Company and the Bank effective as of the date of the Company’s 2024 annual meeting of shareholders
the Company announced that Mensel D. Dean, Jr. and Larry Dees, directors of the Company and the Bank, are retiring from the Boards of Directors of the Company and the Bank effective as of the date of the Annual Meeting pursuant to the Company’s mandatory director retirement age provision set forth in the Company’s Bylaws
Richard A. Farmar, III, Andrew C. Holzwarth and Robert S. Janney, directors of Blue Ridge Bankshares, Inc. (the “Company”) and Blue Ridge Bank, National Association (the “Bank”), a wholly-owned subsidiary of the Company, each notified the Company and the Bank that they are voluntarily retiring from the Boards of Directors of the Company and the Bank effective as of the date of the Company’s 2024 annual meeting of shareholders
On June 24, 2024, the Board of Directors (the “Board”) of NN, Inc. (the “Company”) announced that Michael C. Felcher, Senior Vice President, Chief Financial Officer, tendered his resignation from the Company, effective as of the close of business on June 24, 2024.
Catherine Vaczy, the Company’s then Executive Vice President, General Counsel and Chief Strategy Officer, notified the Company of her intention to resign.
the Company announced that David North, the Company’s Chief Financial Officer (the “CFO”) will retire from the Company, and Laurilee Kearnes will be appointed as the Company’s new CFO
On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.
On June 18, 2024, James Hansen, a member of the Board of Directors (the “Board”) of SideChannel, Inc. (the “Company”) resigned from his position on the Board.
On June 18, 2024, Marinos C. Baghdati, Executive Vice President of Operations of Ring Energy, Inc. (the “Company”), submitted his resignation, effective July 17, 2024.
On June 24, 2024, the Company announced that Stephen D. Brooks who currently serves as the Company’s Executive Vice President of Land, Legal, Human Resources and Marketing, will retire from the Company which will occur on or about July 1, 2024.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
Each of the Company’s directors, including Fahim Ahmed, Jonathan J. Ledecky, Jeanne Manischewitz, Manuel D. Medina, Steven Panagos, Benjamin Phillips, Lisa Sibenac, and Leo Taddeo, will cease being directors of the Company on the Effective Date.
On June 28, 2024, Christa A. D’Alimonte, Executive Vice President, General Counsel and Secretary, will be leaving Paramount Global (the “Company”).
On June 19, 2024, Carrier Global Corporation (the “Company”) announced that Beth A. Wozniak, a member of the Company’s Board of Directors and its Governance and Technology and Innovation committees, will step down from the Board and the committees on which she serves effective immediately.
On June 19, 2024, Bruce Strohm notified the Board that he would be resigning from the Board and all committees of the Board on which he sits, effective as of August 31, 2024.
On June 19, 2024, Ms. Sheri R. Grissom, Executive Vice President and Chief Transformation Officer of Fortune Brands Innovations, Inc. (the "Company"), announced her intention to retire from the Company effective July 1, 2024 and following more than nine years of service with the Company.
On June 19, 2024, David Lazar notified the Company that he voluntarily resigned from his position as Chief Business Development Officer of the Company, effective June 19, 2024.
On June 21, 2024, Shimmick Corporation (the “Company”) announced the departure of Devin J. Nordhagen, Chief Financial Officer, effective June 18, 2024.
On June 18, 2024, the Board of Directors (the “Board”) of F5, Inc. (the “Company”) reviewed and accepted the resignation of Sri Shivananda from his position as a director of the Company, including his membership on each of the Risk Committee and Talent and Compensation Committee, effective June 24, 2024.
On June 17, 2024, Noel Heiks resigned from the Company’s Board of Directors effective on June 17, 2024.
On June 17, 2024, Steven M. Fruchtman informed the board of directors (the “Board”) of Traws Pharma, Inc. (the “Company”) of his intent to resign from his positions of President and Chief Scientific Officer, Oncology.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.